On Friday, Immuneering Corp (NASDAQ: IMRX) was 7.18% up from the session before settling in for the closing price of $6.41. A 52-week range for IMRX has been $1.10 – $10.08.
Over the past five-year period, the drop rate of yearbook sales for the company of the Healthcare sector was -46.45%. When this article was written, the company’s average yearly earnings per share was at 22.30%. With a float of $47.42 million, this company’s outstanding shares have now reached $60.53 million.
Considering the fact that the conglomerate employs 66 people, you should pay attention to its efficiency factor.
Immuneering Corp (IMRX) Breakdown of a Key Holders of the stock
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Immuneering Corp stocks. The insider ownership of Immuneering Corp is 21.66%, while institutional ownership is 13.67%. The most recent insider transaction that took place on Oct 03 ’25, was worth 50,025. In this transaction Director of this company bought 7,500 shares at a rate of $6.67, taking the stock ownership to the 156,766 shares. Before that another transaction happened on Oct 01 ’25, when Company’s Chief Accounting Officer bought 300 for $6.39, making the entire transaction worth $1,917. This insider now owns 27,533 shares in total.
Immuneering Corp (IMRX) Recent Fiscal highlights
Going through the last 3-months fiscal report unveiled on the 9/30/2024, it has been observed that the corporation posted -0.49 earnings per share (EPS) during the time that was better than consensus figure (set at -0.55) by 0.06. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.38 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 22.30% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 2.00% during the next five years compared to -46.45% drop over the previous five years of trading.
Immuneering Corp (NASDAQ: IMRX) Trading Performance Indicators
You can see what Immuneering Corp (IMRX) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 3.70.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.90, a number that is poised to hit -0.39 in the next quarter and is forecasted to reach -1.85 in one year’s time.
Technical Analysis of Immuneering Corp (IMRX)
Compared to the last year’s volume of 1.46 million, its volume of 1.1 million showed lagged in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 82.16%.
During the past 100 days, Immuneering Corp’s (IMRX) raw stochastic average was set at 61.88%, which indicates a significant decrease from 90.11% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.49 in the past 14 days, which was lower than the 0.55 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $6.65, while its 200-day Moving Average is $3.34. Nevertheless, the first resistance level for the watch stands at $7.11 in the near term. At $7.36, the stock is likely to face the second major resistance level. The third major resistance level sits at $7.66. If the price goes on to break the first support level at $6.56, it is likely to go to the next support level at $6.26. Now, if the price goes above the second support level, the third support stands at $6.01.
Immuneering Corp (NASDAQ: IMRX) Key Stats
There are 41,570K outstanding shares of the company, which has a market capitalization of 415.84 million. As of now, sales total 0 K while income totals -61,040 K. Its latest quarter income was 0 K while its last quarter net income were -14,430 K.
